Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing
Open Access
- 26 July 2021
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (10) , 3735-3746
Abstract
Herpes zoster (HZ) is a painful, unilateral rash which occurs upon reactivation of latent varicella zoster virus due to age-related immunity decline or immuno-suppression. In 2019, the recombinant zoster vaccine (RZV) was the first vaccine to be approved in China for HZ prevention. This study aimed to estimate the potential public health impact of RZV vaccination, compared with the status quo of no vaccination, in individuals ≥50 years of age (YOA) in Beijing, by adapting the published ZOster ecoNomic Analysis (ZONA) model. We considered 5% and 50% vaccination coverage for the private market (near-term post-launch) and mass vaccination (long-term) settings respectively. In the base-case analysis of both market settings, second-dose compliance was set to 80%. Coverage and second-dose compliance rates were varied under scenario and sensitivity analyses. In the base case, mass vaccination with RZV was estimated to prevent 435,681 HZ cases, 51,558 postherpetic neuralgia (PHN) cases, and 15,703 cases of other HZ-related complications in the overall ≥50 YOA cohort over their remaining lifetime, compared with no vaccination. Under the same base-case scenario, 14,247 hospitalizations and 1,031,387 outpatient visits could be avoided. The 50–59 YOA cohort had the highest contributions to the overall reduction in HZ cases, its complications and related healthcare resource utilization. Results were robust under numerous scenario and sensitivity analyses. This analysis demonstrates the potential of RZV vaccination to substantially reduce the public health burden of HZ among individuals ≥50 YOA, and may inform appropriate vaccination strategies for HZ prevention, particularly in urban settings within China.Keywords
Funding Information
- GlaxoSmithKline Biologicals SA (GSK study identifier: VEO-000009)
This publication has 29 references indexed in Scilit:
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older AdultsNew England Journal of Medicine, 2015
- Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and AsiaInternational Journal of Infectious Diseases, 2015
- Systematic review of incidence and complications of herpes zoster: towards a global perspectiveBMJ Open, 2014
- Antiviral treatment for preventing postherpetic neuralgiaCochrane Database of Systematic Reviews, 2014
- The Societal Impact of Herpes Zoster and Postherpetic Neuralgia on Patients, Life Partners, and Children of Patients in GermanyThe Scientific World Journal, 2014
- The global epidemiology of herpes zosterNeurology, 2013
- Herpes Zoster Recurrences More Frequent Than Previously ReportedMayo Clinic Proceedings, 2011
- The impact of herpes zoster and post-herpetic neuralgia on quality-of-lifeBMC Medicine, 2010
- IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patientsBMC Medicine, 2010
- Recommendations for the Management of Herpes ZosterClinical Infectious Diseases, 2007